Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Third Fiscal Quarter Ended December 31, 2019
February 10, 2020 08:30 ET
|
Myovant Sciences, Inc.
- 96.7% response rate in Phase 3 HERO study support submission of New Drug Application (NDA) for relugolix monotherapy tablet for advanced prostate cancer in the second quarter of calendar year 2020 ...
Myovant Sciences Announces 88% One-Year Response Rate in Positive Phase 3 LIBERTY Extension Study of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
February 10, 2020 08:25 ET
|
Myovant Sciences, Inc.
Primary efficacy endpoint met with 87.7% response rate at one year; women experienced, on average, an 89.9% reduction in menstrual blood loss Bone mineral density maintained through one year, with no...
Myovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 06, 2020 08:30 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today...
Myovant Sciences Announces Closing of $400 Million Loan Facility, Repayment of Debt, Board of Director Transitions, and Executive Promotions
December 30, 2019 08:30 ET
|
Myovant Sciences, Inc.
Low-interest (3-month LIBOR plus 3%) loan facility from Sumitomo Dainippon Pharma increased to allow repayment of pre-existing debtHiroshi Nomura, President, CEO, and Representative Director of...
Myovant Sciences to Present at the Evercore ISI 2nd Annual HealthCONx Conference on December 3, 2019
November 25, 2019 16:05 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today...
Myovant Sciences Announces 97% Response Rate in Positive Phase 3 HERO Study of Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
November 19, 2019 07:30 ET
|
Myovant Sciences, Inc.
Primary efficacy endpoint met with 96.7% of men achieving sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeksAchieved all six key secondary endpoints, including...
Myovant Sciences to Host Webcast and Conference Call at 8:30 a.m. Eastern Time Tuesday, November 19 to Discuss Results from Phase 3 Study Evaluating Once-Daily, Oral Relugolix in Men with Advanced Prostate Cancer
November 18, 2019 16:05 ET
|
Myovant Sciences, Inc.
BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today...
Myovant Sciences Provides Recent Corporate Updates and Reports Financial Results for Second Fiscal Quarter Ended September 30, 2019
November 12, 2019 08:20 ET
|
Myovant Sciences, Inc.
-Landmark Agreement with Sumitomo Dainippon Pharma to provide major financial backing and safeguards for minority shareholders -Myovant to report top-line data from Phase 3 HERO study in advanced...
Myovant Sciences Enters Landmark Agreement with Sumitomo Dainippon Pharma to Secure Major Financial Backing and Safeguards for Minority Shareholders
October 31, 2019 09:20 ET
|
Myovant Sciences, Inc.
Sumitomo Dainippon Pharma to provide Myovant Sciences with a $350 million, low-interest, five-year term loan facility, with no repayments due until the end of the termOpportunity to access Sumitomo...
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 1 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
October 21, 2019 08:30 ET
|
Myovant Sciences, Inc.
Top-line results for SPIRIT 2 and SPIRIT 1 expected in the first and second quarters of 2020, respectivelyStudies support potential regulatory submission for a single tablet, once-daily treatment of...